ES2156035T3 - Miembros de union especificos para tgf-beta humano, materiales y procedimientos. - Google Patents

Miembros de union especificos para tgf-beta humano, materiales y procedimientos.

Info

Publication number
ES2156035T3
ES2156035T3 ES99102166T ES99102166T ES2156035T3 ES 2156035 T3 ES2156035 T3 ES 2156035T3 ES 99102166 T ES99102166 T ES 99102166T ES 99102166 T ES99102166 T ES 99102166T ES 2156035 T3 ES2156035 T3 ES 2156035T3
Authority
ES
Spain
Prior art keywords
beta
tgf beta
specific binding
procedures
materials
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99102166T
Other languages
English (en)
Spanish (es)
Inventor
Julia Elizabeth Thompson
Andrew James Williams
Tristan John Vaughan
Jonathan Alexander Green
Kevin Stuart Johnson
Philip Ronald Tempest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
Cambridge Antibody Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9520486.3A external-priority patent/GB9520486D0/en
Application filed by Cambridge Antibody Technology Ltd filed Critical Cambridge Antibody Technology Ltd
Application granted granted Critical
Publication of ES2156035T3 publication Critical patent/ES2156035T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES99102166T 1995-10-06 1996-10-07 Miembros de union especificos para tgf-beta humano, materiales y procedimientos. Expired - Lifetime ES2156035T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9520486.3A GB9520486D0 (en) 1995-10-06 1995-10-06 Specific binding members for human transforming growth factor beta; materials and methods
GBGB9601081.4A GB9601081D0 (en) 1995-10-06 1996-01-19 Specific binding members for human transforming growth factor beta;materials and methods

Publications (1)

Publication Number Publication Date
ES2156035T3 true ES2156035T3 (es) 2001-06-01

Family

ID=26307896

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99102166T Expired - Lifetime ES2156035T3 (es) 1995-10-06 1996-10-07 Miembros de union especificos para tgf-beta humano, materiales y procedimientos.
ES96932730T Expired - Lifetime ES2146020T3 (es) 1995-10-06 1996-10-07 Miembros de union especifica para el factor beta de crecimiento de transformacion de humanos; materiales y procedimientos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES96932730T Expired - Lifetime ES2146020T3 (es) 1995-10-06 1996-10-07 Miembros de union especifica para el factor beta de crecimiento de transformacion de humanos; materiales y procedimientos.

Country Status (12)

Country Link
EP (2) EP0945464B1 (enExample)
JP (1) JP4387458B2 (enExample)
AT (2) ATE190650T1 (enExample)
AU (1) AU702049B2 (enExample)
CA (2) CA2233042C (enExample)
DE (2) DE69607191T2 (enExample)
DK (2) DK0945464T3 (enExample)
ES (2) ES2156035T3 (enExample)
GB (2) GB9601081D0 (enExample)
GR (2) GR3033436T3 (enExample)
PT (2) PT945464E (enExample)
WO (1) WO1997013844A1 (enExample)

Families Citing this family (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
AU5087799A (en) 1998-07-06 2000-01-24 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis
ID30316A (id) * 1999-04-09 2001-11-22 Hanmi Pharma Co Ltd METODE UNTUK MENGHITUNG FAKTOR-β1 PERUBAHAN PERTUMBUHAN DAN METODE UNTUK MENDETEKSI KANKER DENGAN FAKTOR-β1 PERUBAHAN PERTUMBUHAN
EP1486560A3 (en) * 1999-04-30 2005-02-09 Cambridge Antibody Technology LTD Specific antibodies and antibody fragments for TGFBETA1
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2001027621A2 (en) * 1999-10-07 2001-04-19 Pharmacia Corporation Competitive inhibition elisa for antibody detection
SE9903895D0 (sv) * 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
AU2002219944B2 (en) 2000-11-28 2008-02-21 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US20020151695A1 (en) * 2000-11-28 2002-10-17 Shuqian Jing Transforming growth factor-beta-related molecules and uses thereof
WO2002064612A2 (en) * 2001-02-09 2002-08-22 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
MXPA03010747A (es) 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
DE10210427A1 (de) 2002-03-09 2003-10-09 Hans Konrad Mueller-Hermelink Humaner monoklonaler Antikörper
EP2270049A3 (en) 2002-04-12 2011-03-09 Medimmune, Inc. Recombinant anti-interleukin-9-antibody
AU2003274463B2 (en) 2002-06-10 2009-10-29 University Of Rochester Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
EP2322559A3 (en) 2002-07-04 2011-08-03 Patrys Limited Neoplasm specific antibodies and uses thereof
DK1551876T3 (da) 2002-10-16 2011-06-14 Purdue Pharma Lp Antistoffer, der binder til celle-associerede ca 125/0722P og fremgangsmåder til anvendelse deraf
GB0224436D0 (en) * 2002-10-21 2002-11-27 Univ Cambridge Tech Polypetides methods and means
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
CA2525647A1 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
WO2005010049A2 (en) * 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
CA2532250A1 (en) 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases
JP2007500132A (ja) 2003-07-25 2007-01-11 アムジェン インコーポレイテッド Ｌｄｃａｍのアンタゴニストおよびアゴニスト、並びにその使用法
EP2128270B1 (en) 2003-08-08 2012-10-03 Genenews Inc. Osteoarthritis biomarkers and uses thereof
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (en) 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
WO2005105841A2 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008513540A (ja) 2004-09-21 2008-05-01 メディミューン，インコーポレーテッド 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
CN103497993A (zh) 2005-02-07 2014-01-08 基因信息公司 轻度骨关节炎生物标志物及其用途
CA2597098C (en) 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
PT1853718E (pt) 2005-02-15 2015-11-12 Univ Duke Anticorpos anti-cd19 e usos em oncologia
EP1858545A2 (en) 2005-03-04 2007-11-28 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
PL1874818T3 (pl) 2005-04-22 2011-09-30 Lilly Co Eli Przeciwciała swoiste wobec TGF-beta 1
JP2008545712A (ja) 2005-05-25 2008-12-18 キュアーディーエム、インク． ペプチド、その誘導体並びに類似体、及びそれらを使用する方法
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
US8249814B2 (en) 2005-10-21 2012-08-21 Genenews Inc. Method, computer readable medium, and system for determining a probability of colorectal cancer in a test subject
EP2862867A3 (en) 2005-10-25 2015-08-05 The Johns Hopkins University Methods and compositions for the treatment of Marfan syndrome and associated disorders
EP2650306A1 (en) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2230252A1 (en) 2006-03-13 2010-09-22 The Johns Hopkins University Augmentation of endothelial thromboresistance
JP2009544761A (ja) 2006-06-14 2009-12-17 マクロジェニクス，インコーポレーテッド 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法
EP2484696B1 (en) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistic hLIGHT-specific human monoclonal antibodies
CN101553254A (zh) 2006-10-03 2009-10-07 建新公司 TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途
US8785400B2 (en) 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
CN101678100A (zh) 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
KR101540823B1 (ko) 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
PT3072525T (pt) 2007-05-14 2018-04-20 Astrazeneca Ab Métodos para reduzir os níveis de basófilos
PT2193142E (pt) 2007-08-30 2015-04-22 Curedm Group Holdings Llc Composições e procedimentos de utilização de peptídeos pro-ilhota e seus análogos
AU2008324800B2 (en) 2007-11-05 2014-03-27 Astrazeneca Ab Methods of treating scleroderma
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
KR20100107501A (ko) 2008-01-18 2010-10-05 메디뮨 엘엘씨 부위 특이적 접합을 위한 시스테인 조작 항체
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
CN102245767B (zh) 2008-10-31 2013-09-18 东丽株式会社 人cxcl1蛋白质的免疫学测定方法
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
CA2749572A1 (en) 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
BRPI1015234A2 (en) 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
MX2012001882A (es) 2009-08-13 2012-04-11 Crucell Holland Bv Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
JP2013509874A (ja) 2009-11-04 2013-03-21 エラスムス ユニバーシティ メディカル センター ロッテルダム 新脈管形成を調節する為の新規化合物及びこれらの化合物を使用する処置方法
EP3117709B1 (en) 2010-03-12 2018-08-01 Genzyme Corporation Combination therapy for treating breast cancer
EP2591000B1 (en) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
US8956868B2 (en) 2010-12-27 2015-02-17 Lsip, Llc Induced pluripotent stem cells produced with a connexin inhibitor and a TGF-β signaling inhibitor
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
US9468612B2 (en) 2011-10-26 2016-10-18 Seattle Children's Hospital Cysteamine in the treatment of fibrotic disease
US9782452B2 (en) 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US20150044178A1 (en) 2011-12-28 2015-02-12 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
JP6367836B2 (ja) 2013-02-07 2018-08-01 ザ ジェネラル ホスピタル コーポレイション Ｔ制御性細胞の増殖または枯渇方法
WO2014129895A1 (en) 2013-02-19 2014-08-28 Stichting Vu-Vumc Means and method for increasing the sensitivity of cancers for radiotherapy
JP6495884B2 (ja) 2013-03-11 2019-04-03 ジェンザイム・コーポレーション 改変抗ｔｇｆベータ抗体および抗原結合フラグメント
BR112015023261A2 (pt) 2013-03-14 2017-07-18 Massachusetts Inst Technology composições e métodos para expansão e cultura de células-tronco epiteliais
EP3003390B1 (en) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
CA2914924A1 (en) 2013-06-13 2014-12-18 Fast Forward Pharmaceuticals B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
CN105764526B (zh) 2013-08-26 2020-12-15 生物技术研发公司 编码抗唾液酸化路易斯a抗原的人抗体的核酸
BR112016007037B1 (pt) 2013-10-01 2023-12-26 National Cancer Center Método para detectar câncer pancreático
CA2927898C (en) 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
LT3148579T (lt) 2014-05-28 2021-05-25 Agenus Inc. Anti-gitr antikūnai ir jų panaudojimo būdai
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
RU2021125449A (ru) 2014-10-01 2021-09-16 Медиммьюн Лимитед Антитела к тикагрелору и способы применения
KR102693806B1 (ko) 2014-12-11 2024-08-09 피에르 파브르 메디카먼트 항-c10orf54 항체들 및 그들의 용도들
EP3789039A1 (en) 2014-12-22 2021-03-10 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
JP6677655B2 (ja) 2015-01-26 2020-04-08 東レ株式会社 胆道癌の検出方法及び胆道癌検出用キット
CN107407681B (zh) 2015-03-02 2020-06-30 东丽株式会社 胰功能异常的检测方法和检测用试剂盒
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
EP3292152A1 (en) 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
DK3447075T3 (da) * 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
WO2016187312A1 (en) 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
WO2017040312A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗ｐｄ−１抗体及びその使用方法
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
RU2018131123A (ru) * 2016-02-17 2020-03-17 Новартис Аг Антитела к tgf-бета2
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
ES2951648T3 (es) * 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
KR20250007678A (ko) 2016-05-13 2025-01-14 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
CA3024465A1 (en) 2016-05-17 2017-11-23 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
KR102543118B1 (ko) 2016-05-27 2023-06-14 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3535294B1 (en) 2016-11-07 2025-02-12 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc. anticorpos anti-cd137 e métodos de uso dos mesmos
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
LT3618863T (lt) 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
BR112019027729A2 (pt) 2017-06-27 2020-08-18 Neuracle Science Co., Ltd anticorpos anti-fam19a5 e seus usos
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
WO2019090263A1 (en) 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CN111727075B (zh) 2017-11-27 2024-04-05 普渡制药公司 靶向人组织因子的人源化抗体
WO2019165077A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
KR20240056644A (ko) 2018-05-10 2024-04-30 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
US12006357B2 (en) 2018-06-26 2024-06-11 Mor Research Applications Ltd. Transthyretin antibodies and uses thereof
KR20250024129A (ko) 2018-07-20 2025-02-18 피에르 파브르 메디카먼트 Vista의 수용체
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
EP3837277A4 (en) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
WO2020041361A1 (en) 2018-08-20 2020-02-27 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
EP3852617B1 (en) 2018-09-20 2025-09-10 SFJ Pharma X, Inc. Use of antibody fragments for reversing ticagrelor activity
US20210380675A1 (en) 2018-09-28 2021-12-09 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
JP2022504287A (ja) 2018-10-03 2022-01-13 スターテン・バイオテクノロジー・ベー・フェー ヒト及びカニクイザルａｐｏｃ３に特異的な抗体、並びにその使用の方法
AU2019361923B2 (en) 2018-10-15 2026-07-09 Five Prime Therapeutics, Inc. Combination therapy for cancer
EP3880711A4 (en) 2018-11-15 2022-12-28 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides
WO2020128927A1 (en) 2018-12-20 2020-06-25 Kyowa Kirin Co., Ltd. Fn14 antibodies and uses thereof
MX2021004504A (es) 2019-01-02 2021-10-01 Neuracle Science Co Ltd Anti-familia con similitud de secuencia 19, anticuerpos del miembro a5 y método de uso de los mismos.
CN119735688A (zh) 2019-02-26 2025-04-01 茵思博纳公司 高-亲和力抗-mertk抗体及其用途
WO2020198731A2 (en) 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
MX2022001882A (es) 2019-08-12 2022-05-30 Aptevo Res & Development Llc Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
CN114585644A (zh) 2019-08-30 2022-06-03 艾吉纳斯公司 抗cd96抗体及其使用方法
EP4025606A1 (en) 2019-09-04 2022-07-13 Y-Biologics Inc. Anti-vsig4 antibody or antigen binding fragment and uses thereof
CN112852738B (zh) * 2019-11-27 2023-02-28 四川省肿瘤医院 一种前列腺癌细胞膜片的制备方法
JP2023513834A (ja) 2020-02-18 2023-04-03 アレクトル エルエルシー Ｐｉｌｒａ抗体及びその使用方法
WO2021176424A1 (en) 2020-03-06 2021-09-10 Ona Therapeutics, S.L. Anti-cd36 antibodies and their use to treat cancer
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
PH12022553106A1 (en) 2020-05-17 2023-11-20 Astrazeneca Uk Liimited Sars-cov-2-antibodies and methods of selecting and using the same
US20230279078A1 (en) 2020-07-20 2023-09-07 Astrazeneca Uk Limited Sars-cov-2 proteins, anti-sars-cov-2 antibodies, and methods of using the same
AU2021328375A1 (en) 2020-08-18 2023-04-13 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof
IL301414A (en) * 2020-09-29 2023-05-01 Zoetis Services Llc Feline antibody variants
US20230382978A1 (en) 2020-10-15 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
AU2021390501A1 (en) 2020-12-01 2023-06-29 Aptevo Research And Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
WO2022184853A1 (en) 2021-03-03 2022-09-09 Pierre Fabre Medicament Anti-vsig4 antibody or antigen binding fragment and uses thereof
WO2022202826A1 (ja) 2021-03-24 2022-09-29 東レ株式会社 悪性膵嚢胞性腫瘍の判定補助方法及び判定補助用キット
CA3220629A1 (en) 2021-05-28 2022-12-01 Tobin J. CAMMETT Methods for detecting cm-tma biomarkers
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
CA3226281A1 (en) 2021-07-30 2023-02-02 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
WO2023192436A1 (en) 2022-03-31 2023-10-05 Alexion Pharmaceuticals, Inc. Singleplex or multiplexed assay for complement markers in fresh biological samples
CR20240528A (es) 2022-04-29 2025-04-04 Astrazeneca Uk Ltd Anticuerpos contra el sars-cov-2 y métodos para utilizarlos
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
CA3266977A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. DIAGNOSTIC AND PROGNOSIS BIOMARKER PROFILES IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)
EP4599089A1 (en) 2022-10-05 2025-08-13 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
CN121729432A (zh) 2023-06-23 2026-03-24 派克西斯肿瘤学公司 抗klrg1抗体及其用途
US20250109187A1 (en) 2023-09-28 2025-04-03 Novavax, Inc. ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
AU2024403128A1 (en) 2023-12-19 2026-06-25 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
US20250361297A1 (en) 2024-03-12 2025-11-27 Adaptam Therapeutics, S.L. Anti- siglec-15 binding molecules and methods of use
WO2026088159A1 (en) 2024-10-24 2026-04-30 Imuno Therapeutics Hla-a2 p53 antibodies and methods of use thereof
WO2026117756A2 (en) 2024-11-27 2026-06-04 Dispatch Biotherapeutics, Inc. Systems and methods for expression of synthetic cancer antigens and cytokine receptors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1539188A (en) * 1987-05-04 1988-11-10 Bristol-Myers Squibb Company TGF-B2 and novel compositions having anti-neoplastic activity
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
JPH0780780B2 (ja) * 1989-09-29 1995-08-30 ラ ホヤ キャンサー リサーチ ファウンデーション 細胞外マトリックスの蓄積防止のためのトランスフォーミング増殖因子βの阻害
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
PT1024191E (pt) * 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993021945A1 (en) * 1992-04-23 1993-11-11 The Regents Of The University Of California METHODS FOR TREATING VASCULAR DISORDERS BY INHIBITING THE ENDOTHELIN STIMULATORY ACTIVITY OF TGF$g(b)
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
GB2288118A (en) * 1994-03-29 1995-10-11 Univ Manchester Wound healing composition
EP0968723B1 (en) * 1994-03-29 2009-07-01 Renovo Limited Healing of wounds or fibrotic disorders using at least one agent against a growth factor

Also Published As

Publication number Publication date
DE69611766T2 (de) 2001-08-02
PT853661E (pt) 2000-08-31
GB9601081D0 (en) 1996-03-20
JP4387458B2 (ja) 2009-12-16
PT945464E (pt) 2001-07-31
DK0945464T3 (da) 2001-05-07
EP0853661B1 (en) 2000-03-15
EP0945464A1 (en) 1999-09-29
CA2599488A1 (en) 1997-04-17
DE69607191T2 (de) 2000-09-28
GR3035775T3 (en) 2001-07-31
DK0853661T3 (da) 2000-08-14
DE69611766D1 (de) 2001-03-15
DE69607191D1 (de) 2000-04-20
AU7140596A (en) 1997-04-30
EP0853661A1 (en) 1998-07-22
ES2146020T3 (es) 2000-07-16
EP0945464B1 (en) 2001-02-07
JP2000500643A (ja) 2000-01-25
CA2233042C (en) 2007-12-18
GB2305921B (en) 1999-10-20
ATE190650T1 (de) 2000-04-15
CA2233042A1 (en) 1997-04-17
GR3033436T3 (en) 2000-09-29
AU702049B2 (en) 1999-02-11
GB2305921A (en) 1997-04-23
ATE199091T1 (de) 2001-02-15
GB9620920D0 (en) 1996-11-27
WO1997013844A1 (en) 1997-04-17

Similar Documents

Publication Publication Date Title
ES2146020T3 (es) Miembros de union especifica para el factor beta de crecimiento de transformacion de humanos; materiales y procedimientos.
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
EP0744958A4 (en) LIBRARIES MADE OF POLYCLONAL ANTIBODIES
PT712307E (pt) Metodos para controlo da populacao de celulas b
ATE117434T1 (de) Gefriergetrocknete zusammensetzung, die ein mit meerrettichperoxydase markiertes fab'-fragment eines gegen menschliches beta-interferon gerichteten antikörpers und trehalose enthält; eia kit, der diese zusammensetzung enthält.
MX9603773A (es) Anticuerpos monoclonales anti-interleucina-8 para el tratamiento de trastornos inflamatorios.
AU2349697A (en) Monoclonal antibodies against the interferon receptor with neutralizing activity against type I interferon
FI912016L (fi) In vitro -menetelmä antigeenispesifisten ihmisen monoklonaalisten vasta-aineiden valmistamiseksi
DE3852054D1 (de) Monoklonale Antikörper gegen Glycolipid-Antigene und ihre Verwendung.
ATE154613T1 (de) Monoklonaler antikörper spezifisch für ein humanes atherom-assoziiertes antigen
AU8185494A (en) Diagnostic assay for alzheimer's disease
AU584690B2 (en) E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
PT941110E (pt) Utilizacao do factor 2 de crescimento dos ceratinocitos
KR890700832A (ko) 그람 음성균의 항원 결정기와 결합하는 사람 단일클론성 항체
AU3283693A (en) Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy
GB9723630D0 (en) M.vaccae preparation and its use

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 945464

Country of ref document: ES